- Home
- DFIN vs ADPT Comparison
DFIN vs ADPT Comparison
Compare DFIN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- ADPT
- Stock Information
- Founded
- DFIN 1983
- ADPT 2009
- Country
- DFIN United States
- ADPT United States
- Employees
- DFIN N/A
- ADPT N/A
- Industry
- DFIN Other Consumer Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DFIN Consumer Discretionary
- ADPT Health Care
- Exchange
- DFIN Nasdaq
- ADPT Nasdaq
- Market Cap
- DFIN 1.6B
- ADPT 1.8B
- IPO Year
- DFIN N/A
- ADPT 2019
- Fundamental
- Price
- DFIN $53.38
- ADPT $13.71
- Analyst Decision
- DFIN Strong Buy
- ADPT Strong Buy
- Analyst Count
- DFIN 3
- ADPT 8
- Target Price
- DFIN $68.67
- ADPT $12.38
- AVG Volume (30 Days)
- DFIN 219.4K
- ADPT 1.7M
- Earning Date
- DFIN 10-30-2025
- ADPT 11-06-2025
- Dividend Yield
- DFIN N/A
- ADPT N/A
- EPS Growth
- DFIN N/A
- ADPT N/A
- EPS
- DFIN 2.79
- ADPT N/A
- Revenue
- DFIN $755,000,000.00
- ADPT $205,216,000.00
- Revenue This Year
- DFIN N/A
- ADPT $32.76
- Revenue Next Year
- DFIN $4.66
- ADPT $15.81
- P/E Ratio
- DFIN $19.17
- ADPT N/A
- Revenue Growth
- DFIN N/A
- ADPT 21.60
- 52 Week Low
- DFIN $37.80
- ADPT $3.98
- 52 Week High
- DFIN $70.55
- ADPT $13.68
- Technical
- Relative Strength Index (RSI)
- DFIN 40.89
- ADPT 61.15
- Support Level
- DFIN $52.66
- ADPT $12.59
- Resistance Level
- DFIN $54.67
- ADPT $13.68
- Average True Range (ATR)
- DFIN 1.40
- ADPT 0.66
- MACD
- DFIN -0.19
- ADPT -0.01
- Stochastic Oscillator
- DFIN 17.41
- ADPT 96.81
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).